#ShortCommunication
▶️Significance of changes in tumor  markers in patients treated with durvalumab plus tremelimumab  combination therapy as a surrogate marker for tumor response to  unresectable hepatocellular carcinoma

👉#LiverX @WileyHealth
#ShortCommunication #LiverX